Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-06-28
2005-06-28
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C548S496000, C562S573000
Reexamination Certificate
active
06911431
ABSTRACT:
Disclosed are methods of inhibiting neovascularization in a subject by administering to the subject a pharmaceutical preparation of R′-Glu-Trp-R″.
REFERENCES:
patent: 3997516 (1976-12-01), Nishimura
patent: 4191753 (1980-03-01), Ryan
patent: 5100873 (1992-03-01), de Castiglione et al.
patent: 5538951 (1996-07-01), Morozov et al.
patent: 5716935 (1998-02-01), Rodgers et al.
patent: 5728680 (1998-03-01), Morozov et al.
patent: 5767087 (1998-06-01), Morozov et al.
patent: 5770576 (1998-06-01), Morozov et al.
patent: 4-279597 (1992-10-01), None
patent: WO 89/06134 (1989-07-01), None
patent: WO 92/17191 (1992-10-01), None
patent: WO 93/08815 (1993-05-01), None
patent: WO 95/03067 (1995-02-01), None
Maione, T.E., “Direct Clinical Applications of Chemokines”, IBC Conference “Chemotactic Cytokines” Oct. 26, 1995.
Le Noble F. A. (European Journal of Pharmacology, 195 (2) 305-6, 1991.
Deinum J. (Endocrinology 126(3) 1673-82, 1990).
Fernandez, L. A. (Journal of laboratory and clinical medicine, 105 (2) 141-5, 1985).
Cameron N. E. (Diabetologia 35 (1) 12_8, 1992).
Fujita Mamoru (Biochemical and Biophysical Research Communications 294 (2) 441-7, 2002).
Maione (Trends in Pharmacological Sciences 11, 457, 1990).
Haber [Prog. Biochem. Pharmacol. (1976), 12 (Drugs Affecting Renin-Angiotensin-Aldosterone Syst., Proc. Kanematsu Conf. Kidney, 5th), 16-32].
Daly, T. J. et al., “High Activity Suppression of Myeloid Progenitor Proliferation by Chimeric Mutants of Interleukin 8 and Platelet Factor 4,” The Journal of Biological Chemistry, vol. 270, No. 40, Oct. 6, 1995, pp. 23282-23292.
DATABASE WPI, Section Ch, Week 9212, Derwent Publications Ltd., London, GB; Class B04, AN 92-094519, XP002023101 & SU, A, 1 642 398 (Rost Med Inst), Apr. 15, 1991. Abstract Only.
DATABASE WPI, Section Ch, Week 9501, Derwent Publications Ltd., London, GB; Class B05, AN 95-004962, XP002023100 & SU, A, 1 827 255 (Kiev Doctor Training Inst), Jul. 15, 1993. Abstract Only.
DATABASE WPI, Section Ch, Week 9511, Derwent Publications Ltd., London, GB; Class B05, AN 95-080267, XP002023102 & RU, C, 2 014 063 (Sochi Spas Physiotherapy Res. Inst), Jun. 15, 1994. Abstract only.
Folkman, J., “What Is the Evidence That Tumors Are Angiogenesis Dependent?,” Journal of the National Cancer Institute, vol. 82, No. 1, Jan. 3, 1990, pp. 4-6.
Frater-Schroder et al., “Tumor necrosis factor type α, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo,” Proc. Natl. Acad. Sci. USA, vol. 84, Aug. 1987, pp. 5277-5281.
Heimark, R.L. et al., “Inhibition of Endothelial Regeneration by Type-Beta Transforming Growth Factor from Platelets,” Science, vol. 233, Sep. 5, 1986, pp. 1078-1080.
Kahn, J.O. et al., “Intralesional Recombinant Tumor Necrosis Factor-α for AIDS-Associated Kaposi's Sarcoma: A Randomized, Double-Blind Trial,” Journal of Acquired Immune Deficiency Syndromes, vol. 2, No. 3, (1989) pp. 217-223.
Knighton, D. et al., “Avascular And Vascular Phases Of Tumor Growth In The Chick Embryo,” Br. J. Cancer, vol. 35, pp. 347-336.
Maione, T.E., “Direct Clinical Applications of Chemokines,” IBC Conference “Chemotactic Cytokines” Oct. 26, 1995.
Maione, T.E. et al., “Development of angiogenesis inhibitors for clinical applications ,” Trends in Pharmaceutical Sciences, vol. 11, Nov. 1990, pp. 457-460.
Nakamura, S. et al., “Kaposi's Sarcoma Cells: Long-Term Culture with Growth Factor from Retrovirus-Infected CD4+ T Cells,” Science, vol. 242, Oct. 21, 1988, pp. 426-430.
Rodionov et al., “The Immunocorrective Therapy of Pyoderma Caused by Staphylococci Multiply Resistant to Antibiotics,” Vestn. Dermatol. Venerol, vol. 1, (Medline Abstract No. 90224329) (1990) pp. 42-45.
Sidky, Y.A. et al., “Inhibition of Angiogenesis by Interferons: Effects on Tumor- and Lymphocyte-induced Vascular Responses,” Cancer Research,. vol. 47, Oct. 1, 1987, pp. 5155-5161.
Wiseman, D.M. et al., “Transforming Growth Factor-Beta (TGFβ) Is Chemotactic For Human Monocytes And Induces Their Expression of Angiogenic Activity,” Biochemical and Biophysical Research Communications, vol. 157, No. 2, Dec. 15, 1988, pp. 793-800.
Blasecki John W.
Green Lawrence R.
Burns Doane Swecker & Mathis L.L.P.
Lukton David
Melmotte, Inc.
Weber Jon
LandOfFree
Pharmaceutical angiostatic dipeptide compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical angiostatic dipeptide compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical angiostatic dipeptide compositions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3467901